

Applicant: Graham P. Allaway et al.  
Serial No: 09/852,238  
Filed: May 9, 2001  
Page 2

**Remarks**

In the October 22, 2001 Notice To Comply, the Examiner stated that the copy of the sequence listing in computer readable form has been submitted, but that the computer readable form (CRF) does not comply with the sequence requirements. The Notice states that applicant must provide a substitute CRF of the sequence listing and a statement that the content of the sequence listing information on the CRF is identical to the written listing and includes no new matter.

In response, applicants submit a substitute paper copy of the sequence listing attached hereto as **Exhibit B** in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a substitute computer readable form (CFR) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as **Exhibit C** a statement in accordance with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invites the Examiner to telephone either of them at the number provided below.

Applicant: . Graham P. Allaway et al.  
Serial No: 09/852,238  
Filed : May 9, 2001

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,


*JD A*

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

*[Signature]* 12-18-01  
John P. White Date  
Reg. No. 28,678  
Spencer H. Schneider  
Reg. No. 45,923

John P. White  
Registration No. 28,678  
Spencer H. Schneider  
Registration No. 45,923  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

# EXHIBIT A

COPY OF PAPERS  
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/852,238	05/09/2001	Graham P. Allaway	51320-AB/JPW/SHS

CONFIRMATION NO. 4501

## FORMALITIES LETTER



\*OC00000006946698\*

 John P. White  
 Cooper & Dunham LLP  
 1185 Avenue of the Americas  
 New York, NY 10036

 received  
 [Signature]

OCT 26 2001

Date Mailed: 10/22/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

B/S

 Customer Service Center  
 Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

# EXHIBIT B



51320-AB.ST25.txt

COPY OF PAPERS  
ORIGINALLY FILED

#9

SEQUENCE LISTING

<110> Graham P. Allaway et al.

<120> USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION

<130> 2048/51320-AB/JPW/SHS

<140> 09/852,238

<141> 2001-09-05

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 38

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 1

caaggctact tccctgattg gcagaactac acaccagg

38

<210> 2

<211> 25

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 2

agcaagccga gtcctgcgtc gagag

25

<210> 3

<211> 23

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 3  
 gggactttcc gctggggact ttc  
 23

<210> 4  
 <211> 33  
 <212> DNA  
 <213> artificial sequence

<220>  
 <223> primer

<400> 4  
 cctgttcggg cgccactgct agagattttc cac  
 33

<210> 5  
 <211> 31  
 <212> PRT  
 <213> human

<400> 5

Met	Asp	Tyr	Gln	Val	Ser	Ser	Pro	Ile	Tyr	Asp	Ile	Asn	Tyr	Tyr	Thr
1				5					10					15	

Ser	Glu	Pro	Cys	Gln	Lys	Ile	Asn	Val	Lys	Gln	Ile	Ala	Ala	Arg
			20					25					30	

<210> 6  
 <211> 15  
 <212> PRT  
 <213> human

<400> 6

His	Tyr	Ala	Ala	Ala	Gln	Trp	Asp	Phe	Gly	Asn	Thr	Met	Cys	Gln
1				5					10					15

<210> 7  
 <211> 32  
 <212> PRT

<213> human

<400> 7

Arg Ser Gln Lys Glu Gly Leu His Tyr Thr Cys Ser Ser His Phe Pro  
1 5 10 15

Tyr Ser Gln Tyr Gln Phe Trp Lys Asn Phe Gln Thr Leu Lys Ile Val  
20 25 30

<210> 8

<211> 17

<212> PRT

<213> human

<400> 8

Gln Glu Phe Phe Gly Leu Asn Asn Cys Ser Ser Ser Asn Arg Leu Asp  
1 5 10 15

Gln

<210> 9

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 9

aagcttggag aaccagcggg taccatggag gggatc  
36

<210> 10

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> primer



<400> 10  
gtctgagtct gagtcaagct tggagaacca  
30

<210> 11  
<211> 41  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 11  
ctcgagcatc tgtgttagct ggagtgaaaa cttgaagact c  
41

<210> 12  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 12  
gtctgagtct gagtccctcga gcatctgtgt  
30

<210> 13  
<211> 32  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 13  
aagcttcaga gagaagccgg gatggaaact cc  
32

<210> 14  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>

<223> primer

<400> 14

gtctgagtct gagtcaagct tcagagagaa  
30

<210> 15

<211> 32

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 15

ctcgagctga gtcagaaccc agcagagagt tc  
32

<210> 16

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 16

gtctgagtct gagtcctcga gctgagtcag  
30

<210> 17

<211> 32

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 17

aagcttcagt acatccacaa catgctgtcc ac  
32

<210> 18  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 18  
gtctgagtct gagtcaagct tcagtacatc  
30

<210> 19  
<211> 31  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 19  
ctcgagcctc gttttataaaa ccagccgaga c  
31

<210> 20  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 20  
gtctgagtct gagtcctcga gcctcgtttt  
30

<210> 21  
<211> 29  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 21

aagcttcagg gagaagtgaa atgacaacc  
29

<210> 22  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 22  
gtctgagtct gagtcaagct tcagggagaa  
30

<210> 23  
<211> 33  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 23  
ctcgagcaga cctaaaacac aatagagagt tcc  
33

<210> 24  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 24  
gtctgagtct gagtcctcga gcagacctaa  
30

<210> 25  
<211> 34  
<212> DNA  
<213> artificial sequence

<220>

<223> primer

<400> 25

aagcttctgt agagttaaaa aatgaacccc acgg  
34

<210> 26

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 26

gtctgagtct gagtcaagct tctgtagagt  
30

<210> 27

<211> 34

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 27

ctcgagccat ttcatttttc tacaggacag catc  
34

<210> 28

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> primer

<400> 28

gtctgagtct gagtccctcga gccatttcac  
30

<210> 29

<211> 39  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 29  
gtctgagtct gagtcaagct taacaagatg gattatcaa  
39

<210> 30  
<211> 39  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer

<400> 30  
gtctgagtct gagtctctga gtccgtgtcg caagcccac  
39

# EXHIBIT C



COPY OF PAPERS  
ORIGINALLY FILED

# 9

Dkt. No. 51320-AB/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Graham P. Allaway, et al.  
Serial No. : 09/852,238  
Filed : May 9, 2001  
For : USES OF A CHEMOKINE RECEPTOR FOR  
INHIBITING HIV-1 INFECTION

1185 Avenue of the Americas  
New York, New York 10036  
December 18, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted in connection with the above-identified application, has the same information as the pages attached hereto as **Exhibit B**, and entitled "Sequence Listing" and contains no new matter.

Respectfully submitted,

Spencer Schneider  
Registration No. 45,923  
c/o Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400